Hsiao Tzu-Hung, Chiu Yu-Chiao, Chen Yu-Heng, Hsu Yu-Ching, Chen Hung-I Harry, Chuang Eric Y, Chen Yidong
Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.
Greehey Children's Cancer Research Institute, University of Texas Health Science Center, San Antonio, TX, United States.
Comb Chem High Throughput Screen. 2018;21(2):74-83. doi: 10.2174/1574888X13666180105125347.
The number of anticancer drugs available currently is limited, and some of them have low treatment response rates. Moreover, developing a new drug for cancer therapy is labor intensive and sometimes cost prohibitive. Therefore, "repositioning" of known cancer treatment compounds can speed up the development time and potentially increase the response rate of cancer therapy. This study proposes a systems biology method for identifying new compound candidates for cancer treatment in two separate procedures.
First, a "gene set-compound" network was constructed by conducting gene set enrichment analysis on the expression profile of responses to a compound. Second, survival analyses were applied to gene expression profiles derived from four breast cancer patient cohorts to identify gene sets that are associated with cancer survival. A "cancer-functional gene set- compound" network was constructed, and candidate anticancer compounds were identified. Through the use of breast cancer as an example, 162 breast cancer survival-associated gene sets and 172 putative compounds were obtained.
We demonstrated how to utilize the clinical relevance of previous studies through gene sets and then connect it to candidate compounds by using gene expression data from the Connectivity Map. Specifically, we chose a gene set derived from a stem cell study to demonstrate its association with breast cancer prognosis and discussed six new compounds that can increase the expression of the gene set after the treatment.
Our method can effectively identify compounds with a potential to be "repositioned" for cancer treatment according to their active mechanisms and their association with patients' survival time.
目前可用的抗癌药物数量有限,其中一些药物的治疗反应率较低。此外,开发一种用于癌症治疗的新药需要耗费大量人力,而且有时成本过高。因此,已知癌症治疗化合物的“重新定位”可以加快开发时间,并有可能提高癌症治疗的反应率。本研究提出了一种系统生物学方法,通过两个独立的程序来识别用于癌症治疗的新化合物候选物。
首先,通过对化合物反应的表达谱进行基因集富集分析,构建一个“基因集-化合物”网络。其次,对来自四个乳腺癌患者队列的基因表达谱进行生存分析,以识别与癌症生存相关的基因集。构建一个“癌症-功能基因集-化合物”网络,并识别候选抗癌化合物。以乳腺癌为例,获得了162个与乳腺癌生存相关的基因集和172个推定化合物。
我们展示了如何通过基因集利用先前研究的临床相关性,然后通过使用来自连通性图谱的基因表达数据将其与候选化合物联系起来。具体来说,我们选择了一个来自干细胞研究的基因集来证明其与乳腺癌预后的关联,并讨论了六种在治疗后可增加该基因集表达的新化合物。
我们的方法可以根据化合物的作用机制及其与患者生存时间的关联,有效地识别具有“重新定位”用于癌症治疗潜力的化合物。